Drug Profile
Leukocyte interleukin - CEL-SCI
Alternative Names: BC-IL; Buffy coat interleukins - CEL-SCI; Interleukin-2 cocktail - CEL-SCI; Leucocyte Interleukin injection - CEL-SCI; MultikineLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator CEL-SCI Corporation
- Developer CEL-SCI Corporation; Ergomed; Naval Medical Research Center; Orient Europharma; Teva Pharmaceutical Industries
- Class Antineoplastics; Antiretrovirals; Antivirals; Granulocyte-macrophage colony-stimulating factors; Interferons; Interleukins
- Mechanism of Action Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Head and neck cancer
- No development reported Cervical dysplasia; Condylomata acuminata
- Discontinued Breast cancer; HIV infections; Prostate cancer
Most Recent Events
- 13 Feb 2024 CEL-SCI Corporation announces intention to submit the proposed study protocol to the US FDA in the first quarter of 2024
- 09 Feb 2024 CEL-SCI Corporation plans a confirmatory trial for Head and neck cancer (Perilesional)
- 06 Feb 2024 CEL-SCI Corporation plans to seek accelerated approval for Leukocyte interleukin in Head and neck cancer